Earnings Call Summary | BAYER AG(BAYZF.US) Q1 2024 Earnings Conference
Earnings Call Summary | BAYER AG(BAYZF.US) Q1 2024 Earnings Conference
The following is a summary of the Bayer AG (BAYZF) Q1 2024 Earnings Call Transcript:
以下是拜耳公司（BAYZF）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Bayer reported Q1 sales of €13.8 billion, slightly lower than the previous year.
Core earnings per share stood at €2.82, also slightly below the previous year's earnings.
The company's free cash flow was negative €2.6 billion, which marked an improvement from Q1 of the preceding year, largely due to lower litigation payouts.
Crop Science unit sales were down by 3%, impacted by adverse weather conditions and lower glyphosate pricing, while the Pharmaceuticals business saw a 4% rise in sales largely due to strong performance from their new launched products.
拜耳報告稱，第一季度銷售額爲138億歐元，略低於上年。
每股核心收益爲2.82歐元，也略低於上一年的收益。
該公司的自由現金流爲負26億歐元，與去年第一季度相比有所改善，這主要是由於訴訟支出減少。
受惡劣天氣條件和草甘膦價格下跌的影響，作物科學部門的銷售額下降了3％，而製藥業務的銷售額增長了4％，這主要是由於其新推出的產品的強勁表現。
Business Progress:
業務進展：
Both Pharmaceutical products, Nubeqa and Kerendia, are seeing growth.
Bayer introduced Iberogast to the US market after its success in Europe.
Significant reductions in management roles are expected to save approximately €500 million in 2024 and target savings of $2 billion by 2026.
As part of their Dynamic Shared Ownership, Bayer is consolidating roles and designing teams for greater impact.
Bayer's Pharmaceuticals team expects to have readouts of Kerendia's first Phase 3 study in heart failure and Nubeqa's ARANOTE trial.
Despite competition, Eylea is showing positive longevity and volume increases in most territories.
Their Consumer Health segment has globally initiated around 90 teams, with one team reducing the product launch time from 36 months to 9 months in the ASEAN region.
Bayer is also working towards improving its supply situation for better product availability and gaining market share in key products.
Nubeqa和Kerendia這兩種製藥產品都在增長。
拜耳在歐洲取得成功後，將Iberogast引入了美國市場。
預計在2024年大幅裁減管理職位將節省約5億歐元，目標是到2026年節省20億美元。
作爲其動態共享所有權的一部分，拜耳正在整合角色和設計團隊，以提高影響力。
拜耳製藥團隊預計將公佈克倫迪亞首項心力衰竭三期研究和努貝卡的ARANOTE試驗。
儘管存在競爭，但Eylea在大多數地區的使用壽命和銷量都呈現出積極的增長態勢。
他們的消費者健康部門已在全球組建了約90個小組，其中一個團隊將東盟地區的產品發佈時間從36個月縮短到9個月。
拜耳還努力改善其供應狀況，以提高產品可用性並獲得關鍵產品的市場份額。
More details: BAYER AG IR
更多詳情： 拜耳股份公司
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。